1. Nanoparticle-based Olaparib delivery enhances its effect, and improves drug sensitivity to cisplatin in triple negative breast cancer
   Shentao Zhang et al, 2022, Journal of Drug Delivery Science and Technology CrossRef
2. Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
   Inken Flörkemeier et al, 2022, International Journal of Molecular Sciences CrossRef
3. Cisplatin for cancer therapy and overcoming chemoresistance
   Ranmali Ranasinghe et al, 2022, Heliyon CrossRef
4. Analysis of olaparib efficacy in patients with serous ovarian cancer
   null null et al, 2023, Hirurg (Surgeon) CrossRef
5. Hybrid nano-architectures loaded with metal complexes for the co-chemotherapy of head and neck carcinomas
   Melissa Santi et al, 2023, Journal of Materials Chemistry B CrossRef
6. Identification of druggable targets from the interactome of the Androgen Receptor and Serum Response Factor pathways in prostate cancer
   Haleema Azam et al, 2024, PLOS ONE CrossRef
7. PARP deficiency causes hypersensitivity to Taxol through oxidative stress induced DNA damage
   Junko Maeda et al, 2023, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis CrossRef
8. Triple Combinations of Histone Lysine Demethylase Inhibitors with PARP1 Inhibitor–Olaparib and Cisplatin Lead to Enhanced Cytotoxic Effects in Head and Neck Cancer Cells
   Dawid Dorna et al, 2024, Biomedicines CrossRef
9. PROSPECTS FOR THE USE OF PLATINUM DRUGS
   Sadkova Yu.A. et al, 2023, "Medical & pharmaceutical journal "Pulse" CrossRef
10. Circ_0002722-induced regulation of YAP promotes platinum resistance in oral squamous cell carcinoma: Implications for verteporfin therapy
    Hsiao-Chi Tsai et al, 2024, Biochemical Pharmacology CrossRef
11. The Conjugates of Indolo[2,3-b]quinoline as Anti-Pancreatic Cancer Agents: Design, Synthesis, Molecular Docking and Biological Evaluations
    Marcin Cybulski et al, 2024, International Journal of Molecular Sciences CrossRef